People with Parkinsons disease given deep brain stimulation (DBS) targeting the right side of the brain experienced fewer cognitive side effects following treatment compared with those who received the procedure to the left side of the brain, according to new findings from a clinical trial. Deep brain stimulation, commonly called DBS, is a surgical treatment for Parkinsons that involves implanting an electrode into the brain to deliver gentle electrical stimulation to specific brain regions. Continue reading →

Physical Therapy for Parkinsons Disease Physical therapy and exercise are crucial aspects of Parkinsons disease (PD) treatment and APDA has many ways to help you get up and moving. Many people are curious about why exercise is so important for someone with PD and what type of exercise is best for someone with PD, which weve talked about in earlier programs and blog posts. This previous Q+A session also addresses the best way to approach exercise and PD. Continue reading →

Christine Lebrun-Frenay, MD, PhD, FAAN Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, held April 22-27, in Boston, Massachusetts, findings from the phase 3 TERIS study (NCT03122652) showed that treatment with teriflunomide (Aubagio; Sanofi) significantly reduced the time to first clinical event in patients with radiologically isolated syndrome (RIS), often considered the presymptomatic phase of multiple sclerosis (MS). Continue reading →

Newswise In Srmland, Sweden, music therapy is offered as a method of treatment for people living with chronic pain. Currently, the effects of what is known as the FMT method are being investigated through a research project at Mlardalen University (MDU) Continue reading →

The Global Parkinson's Disease Treatments market research report 2023 provides an in-depth analysis of an industry or market, covering essential aspects such as market size, growth potential, competitive landscape, consumer behaviour, and other significant factors influencing the market. This report is a valuable resource for businesses seeking to enter or expand their presence in the market, as it enables them to make informed strategic decisions. Continue reading →

WATCH TIME: 6 minutes "When we think about rapid progressive dementia, it is a big category. One thing that we've learned from our experience enrolling patients and assessing them is that if you take all comers, including inpatients and outpatients, there's a sizable proportion of patients that have a potentially treatment responsive because of rapid progressive dementia." Rapidly progressive dementias (RPDs) are a collection of different heterogeneous diseases that include encephalopathies and atypically rapid presentations of more common neurodegenerative diseases. Researchers note that some of these conditions are treatable, although others require prompt diagnosis because of their potential infectivity.1 Gregory Day, MD, MSc, MSCI, FAAN, gave a talk on RPD in a seminar dedicated to aging, dementia, cognitive, and behavioral neurology at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27, in Boston, Massachusetts Continue reading →

Parkinson's causes uncontrollable tremors that are the most well known symptom of the disease, but there are other early signs you might not know. Symptoms of Parkinson's disease usually begin gradually and worsen over time Continue reading →

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gains lead program for GBA1 Parkinsons disease. The Companys Swiss Accelerator innovation project supported by Innosuisse entitled Harnessing Structurally Targeted Allosteric Regulators to treat Parkinsons Disease includes clinical pharmacology and preclinical studies with the Companys drug candidate GT-02287, which will be conducted as the lead program progresses through Phase 1 and Phase 2 clinical studies in GBA1 Parkinsons disease Continue reading →

Texas Public Radio will partner with UT Health San Antonio to serve the community at the next Think Science live program, sharing the latest information about the connections between brain and body health and new developments in the fight against dementia and Alzheimers disease. Continue reading →

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes key companies continuously working towards developing Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Continue reading →